Aliskiren inhibits renin-mediated complement activation
Certain kidney diseases are associated with complement activation although a renal triggering factor has not been identified. Here we demonstrated that renin, a kidney-specific enzyme, cleaves C3 into C3b and C3a, in a manner identical to the C3 convertase. Cleavage was specifically blocked by the renin inhibitor aliskiren. Renin-mediated C3 cleavage and its inhibition by aliskiren also occurred in serum. Generation of C3 cleavage products was demonstrated by immunoblotting, detecting the cleavage product C3b, by N-terminal sequencing of the cleavage product, and by ELISA for C3a release. (Source: Kidney International)
Source: Kidney International - June 5, 2018 Category: Urology & Nephrology Authors: Zivile D. B ékássy, Ann-Charlotte Kristoffersson, Johan Rebetz, Ramesh Tati, Anders I. Olin, Diana Karpman Tags: Basic Research Source Type: research
Aliskiren: Preclinical evidence for the treatment of hyperproliferative skin disorders
Publication date: August 2018 Source:Biomedicine & Pharmacotherapy, Volume 104 Author(s): Priscila Lúcia Pawloski, Camila Guimarães Moreira, Cintia Delai Silva Horinouchi, Daniel Fernandes, Luiz Renato Olchanheski, Willian Machado, Daniela Almeida Cabrini, Michele Dietrich, Kátia Paludo, Michel Fleith Otuki Psoriasis is a complex inflammatory and hyperproliferative skin disease. The pathogenesis and mechanisms involved are not completely understood, which makes treatment a difficult issue. Angiotensin II, the most active peptide of the renin-angiotensin system, seems to be involved in processes relat...
Source: Biomedicine and Pharmacotherapy - May 15, 2018 Category: Drugs & Pharmacology Source Type: research
Sympathoexcitation following intermittent hypoxia in rat is mediated by circulating angiotensin II acting at the carotid body and subfornical organ.
This article is protected by copyright. All rights reserved.
PMID: 29645283 [PubMed - as supplied by publisher] (Source: The Journal of Physiology)
Source: The Journal of Physiology - April 12, 2018 Category: Physiology Authors: Kim SJ, Fong AY, Pilowsky PM, Abbott SBG Tags: J Physiol Source Type: research
The Effect of Aliskiren on Exercise Capacity in Older Patients with Heart Failure and Preserved Ejection Fraction: A Randomized, Placebo-Controlled, Double-Blind Trial
Publication date: Available online 4 April 2018 Source:American Heart Journal Author(s): Bharathi Upadhya, Peter H. Brubaker, Timothy M. Morgan, Joel D Eggebeen, Geoffrey T. Jao, Kathryn P. Stewart, Dalane W. Kitzman In older patients (70±7years) with chronic well-compensated heart failure with preserved ejection and controlled blood pressure, 6months treatment with aliskiren (direct renin inhibitor) showed non-significant trends for modest improvements in peak exercise oxygen consumption (14.9±0.2ml/kg/min versus 14.4±0.2ml/kg/min; P =.10, trend) and ventilatory anaerobic threshold (888±19m//min versus 841±1...
Source: American Heart Journal - April 5, 2018 Category: Cardiology Source Type: research
Efficacy of aliskiren supplementation for heart failure : A meta-analysis of randomized controlled trials.
CONCLUSION: Aliskiren supplementation was found to significantly decrease NT-proBNP levels and plasma renin activity and to improve plasma renin concentration in the setting of heart failure.
PMID: 29470612 [PubMed - as supplied by publisher] (Source: Herz)
Source: Herz - February 24, 2018 Category: Cardiology Tags: Herz Source Type: research
Correction: Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis.
Authors: Fu S, Wen X, Han F, Long Y, Xu G
Abstract
[This corrects the article DOI: 10.18632/oncotarget.19382.].
PMID: 29465717 [PubMed - in process] (Source: Oncotarget)
Source: Oncotarget - February 23, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Food-drug interactions precipitated by fruit juices other than grapefruit juice: An update review
Publication date: Available online 15 February 2018 Source:Journal of Food and Drug Analysis Author(s): Meng Chen, Shu-yi Zhou, Erlinda Fabriaga, Pian-hong Zhang, Quan Zhou This review addressed drug interactions precipitated by fruit juices other than grapefruit juice based on randomized controlled trials (RCTs). Literature was identified by searching PubMed, Cochrane Library, Scopus and Web of Science till December 30 2017. Among 46 finally included RCTs, six RCTs simply addressed pharmacodynamic interactions and 33 RCTs studied pharmacokinetic interactions, whereas seven RCTs investigated both pharmacokinetic and...
Source: Journal of Food and Drug Analysis - February 15, 2018 Category: Food Science Source Type: research
Arterial wall hypertrophy is ameliorated by α2-adrenergic receptor antagonist or aliskiren in kidneys of angiotensinogen-knockout mice
ConclusionsAlpha2-AR signaling is one of the causes of persistent renal arterial hypertrophy inAtg−/− mice. Aliskiren also angiotensinogen-independently reduces the extent of renal arterial hypertrophy, partly thorough downregulation of α2-ARs. Although renal arterial hypertrophy inAtg−/− mice appears to be of multifactorial origin, TGF- β1 may play a key role in the persistence of such hypertrophy. (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - December 11, 2017 Category: Urology & Nephrology Source Type: research
Comparison of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol
Conclusions Among patients with MS, the addition of aliskiren to beta-blocker treatment did not significantly improve central aortic stiffness during a 24-week period. (Source: Revista Espanola de Cardiologia)
Source: Revista Espanola de Cardiologia - December 1, 2017 Category: Cardiology Source Type: research
Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis.
In conclusion, this meta-analysis demonstrated that aliskiren in combination therapy with ACEs/ARBs could control BP effectively, but is associated with increasing risks of hyperkalaemia and kidney injury, and have no benefit in preventing of major cardiovascular events.
PMID: 29179525 [PubMed] (Source: Oncotarget)
Source: Oncotarget - November 29, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Aliskiren and valsartan in combination is a promising therapy for hypertensive renal injury in rats.
CONCLUSION: These results suggest that therapies aimed at different targets within the RAAS may have additional effects in attenuating structural injury in experimental hypertensive nephropathy.
PMID: 29172824 [PubMed - as supplied by publisher] (Source: Clinical and Experimental Hypertension)
Source: Clinical and Experimental Hypertension - November 27, 2017 Category: Cardiology Authors: Abdel Kawy HS Tags: Clin Exp Hypertens Source Type: research
Aliskiren for heart failure: a systematic review and meta-analysis of randomized controlled trials.
Conclusions: Aliskiren, either used alone or combined with standard medical therapy, does not significantly reduce the all-cause mortality or cardiovascular mortality of heart failure patients. Although aliskiren does not cause statistically higher adverse events, its adverse events may not be neglected.
PMID: 29152151 [PubMed] (Source: Oncotarget)
Source: Oncotarget - November 22, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - November 16, 2017 Category: Cardiology Source Type: research
Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial
European Journal of Heart Failure,Volume 20, Issue 4, Page 677-686, April 2018. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - November 16, 2017 Category: Cardiology Authors: Muthiah
Vaduganathan
,
Baljash
Cheema
,
Erin
Cleveland
,
Kamya
Sankar
,
Haris
Subacius
,
Gregg C.
Fonarow
,
Scott D.
Solomon
,
Eldrin F.
Lewis
,
Stephen J.
Greene
,
Aldo P.
Maggioni
,
Michael
B öhm
,
Faiez
Zann Source Type: research
Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy [Original Research Articles]
Conclusions
Despite younger age, less comorbidity, and comprehensive use of conventional HF therapies, patients with Chagasic HF with reduced ejection fraction continue to have worse quality of life and higher hospitalization and mortality rates compared with other etiologies.
Clinical Trial Registration
PARADIGM-HF: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255; ATMOSPHERE: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00853658. (Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - November 15, 2017 Category: Cardiology Authors: Shen, L., Ramires, F., Martinez, F., Bodanese, L. C., Echeverria, L. E., Gomez, E. A., Abraham, W. T., Dickstein, K., Kober, L., Packer, M., Rouleau, J. L., Solomon, S. D., Swedberg, K., Zile, M. R., Jhund, P. S., Gimpelewicz, C. R., McMurray, J. J. V., o Tags: Heart Failure Original Research Articles Source Type: research
